問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Tzu Chi Hospital (在職)

Division of Urology

更新時間：2023-09-19

楊緒棣
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊緒棣

List

5Cases

2020-05-18 - 2023-12-31

Phase III

Active
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated Recurrent Urinary Tract Infections (rUTIs) in Women

  • Condition/Disease

    Recurrent Urinary Tract Infections (rUTIs)

  • Test Drug

    U101

Participate Sites
19Sites

Not yet recruiting7Sites

Recruiting6Sites

Terminated6Sites

2014-10-01 - 2024-12-30

Phase II

A PHASE II, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MCS® IN PROSTATE CANCER PREVENTION

  • Condition/Disease

    PROSTATE CANCER

  • Test Drug

    MCS®

Participate Sites
21Sites

Recruiting6Sites

Study ended15Sites

2007-05-01 - 2009-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2016-04-01 - 2019-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2013-08-01 - 2017-12-31

Phase III

A Randomized, Double-blind, Parallel Group Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride (0.5mg) and Tamsulosin (0.2mg) With Tamsulosin (0.2mg) Monotherapy, Administered Once Daily for 2 Years, on the Improvement of Symptoms and Health Outcomes in Men With Moderate to Severe Benign Prostatic Hyperplasia

  • Condition/Disease

    Moderate to Severe Benign Prostatic Hyperplasia

  • Test Drug

    (1) AVODART SOFT CAPSULES；(2) Harnalidge D tablets

Participate Sites
8Sites

Not yet recruiting1Sites

Terminated7Sites

鄭鴻琳
National Taiwan University Hospital

Division of Urology

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB